ResearcherGeorgetown University Medical CenterNo recent work listed
Insoo Bae
Matched on OpenAlex author ID A5110693758; NIH RePORTER profile ID 7041174.
Their work
- Papers
- 8 (first author 1, last author 5)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 5
2011: 1 grant · 2012: 5 papers · 2013: 1 paper · 2014: 2 papers
Papers 8
- Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Last author DOI 10.3892/ijo.2013.2229↗
- Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells. Co-author DOI 10.3892/ijo.2014.2357↗
- Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. Last author DOI 10.1111/jcmm.12101↗
- Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. Last author DOI 10.1097/mpa.0b013e318230f71a↗
- Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. Last author DOI 10.3892/ijo.2012.1516↗
- BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells. Last author DOI 10.3892/ijo.2012.1672↗
- ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. First author DOI 10.3892/or.2011.1503↗
- Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Co-author PMID 22399597↗
Grants 1
Closest collaborators
The 5 strongest of 5 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Yeon-Sun Seong · 7 shared papers, 2012–2014
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. DOI 10.1097/mpa.0b013e318230f71a↗
- Hong-Quan Duong · 5 shared papers, 2012–2014
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells. DOI 10.3892/ijo.2012.1672↗
- Yong Weon Yi · 4 shared papers, 2012–2014
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. DOI 10.1097/mpa.0b013e318230f71a↗
- Young Bin Hong · 4 shared papers, 2012–2014
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. DOI 10.1097/mpa.0b013e318230f71a↗
- Paper Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. PMID 22399597↗
- Yeon Jeong Kim · 2 shared papers, 2012–2013
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.